Alnylam Pharmaceuticals | ALNY - Ebitda


Alnylam Pharmaceuticals reported $145.22M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Agios Pharmaceuticals USD -120.31M 4.82M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Arrowhead Research USD 57.17M 7.03M Dec/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Incyte USD 367.97M 46.53M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Moderna USD -790M 582M Dec/2025
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 5.84B 235M Sep/2025
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Sanofi EUR 5.66B 3.77B Sep/2025
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Takeda JPY 150.25B 297.88B Mar/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026
Xencor USD -51.05M 55.28M Dec/2025